Navigation Links
Juvéderm Voluma Declared Effective by the FDA
Date:5/16/2013

Los Angeles, CA (PRWEB) May 16, 2013

According to an April 30, 2013 CNBC article, titled “FDA Staff Says Allergan's New Dermal Filler Effective” (Go to goo.gl/kQJKk), the US Food and Drug Administration (FDA) recently declared that Juvéderm Voluma XC, a dermal filler product manufactured by Allergan Inc., is effective in correcting volume deficits in the middle of the face. The FDA reported that after six months of Juvéderm Voluma XC treatments, there is a significant improvement in the appearance of facial wrinkles and folds in the center of the face.

“I look forward to being able to offer Juvéderm Voluma XC to my patient,” says Dr. Simon Ourian, Medical Director of Epione Beverly Hills. “Everything I’ve heard and read until now indicates that it works well to restore lost facial volume.”

The article noted that the FDA reviewers who conducted the preliminary review of Juvéderm Voluma XC indicated that if the FDA advisory panel approved the dermal filler, Allergan should be compelled to perform further safety tests. Before the approval was announced, some analysts had predicted that based on Allergan Inc.’s track record and the quality of the other products manufactured by the company, there was a high likelihood of the FDA clearing Juvéderm Voluma XC.

Although two of the FDA reviewers initially dissented from the opinion, on May 2, 2013 the independent advisory panel of the Federal Drug Administration voted on the safety, effectiveness and risk benefit profile of this dermal filler, and unanimously declared that is an effective injectable that has the ability to correct age related problems such as folds and wrinkles in the mid-face.

“It is important to note that prior to the FDA's declaration that Juvéderm Voluma XC is effective, it had previously approved an earlier version of Juvéderm in 2006,” says Dr. Ourian, “and I’ve been using it in my practice since that time. I found it to be an effective product and I expect Juvéderm Voluma to be a benefit to my patients too.”

Dr. Ourian has been a pioneer in laser technology and non-invasive aesthetic procedures including Restylane, Juvéderm, Radiesse and Sculptra. These treatments are used for the correction or reversal of a variety of conditions such as acne, acne scars, skin discoloration, wrinkles, stretch marks, varicose veins, cellulite, and others. More information about the pending approval of Juvéderm Voluma XC can be found on Epione’s website.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10738326.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Days for Girls International Declared a Nike Girl Effect Champion
2. Pelvic organ prolapse surgery less effective than expected
3. Procedure for Incontinence in Women May Lose Effectiveness With Time
4. New Global Study Pinpoints Main Causes of Childhood Diarrheal Diseases, Suggests Effective Solutions
5. Weight Loss Solutions
6. How “Customized Fat Loss” Helps People Lose Fat Effectively – V kool
7. Dermatologists in San Diego Say Botox is a Safe & Effective Treatment for Migraine & Tension Headache Relief
8. Silk and cellulose biologically effective for use in stem cell cartilage repair
9. Exercise proves to be ineffective against care home depression
10. Weight loss surgery safe and effective for an expanded group of patients
11. Mariner Biomedical Announces Results From an Independent Laboratory Confirming Deter Insect Repellent™ Effectively Repels Mosquitoes for 6 Hours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version of ... differs significantly from the American Health Care Act, which the House passed in May, ... will have to take up the Senate version as-is, if it passes. , The ...
(Date:6/25/2017)... ... 25, 2017 , ... CareSet Labs released the Root NPI Graph today at ... new, greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. ... subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... Erie, PA (PRWEB) , ... June 24, 2017 ... ... was held in Erie, PA at the Sheraton Erie Bayfront and Erie Convention ... hands-on evidence based medicine experience, exhibits, a student quiz bowl, award and scholarship ...
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing the ... the summer months provide more than warmer temperatures that are perfect for BBQ’s and ... from direct exposure to the sun. When it comes to the security of homes ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
Breaking Medicine Technology: